C3, fwiw mate my take....
This says a lot...
SYDNEY, AUSTRALIA – 21 September 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or
“the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for
cancer and autoimmune disease, is pleased to announce it will report final Overall Survival (OS) data from its
Phase IIb AIPAC clinical trial evaluating lead product candidate eftilagimod alpha (“efti” or “IMP321”) in
metastatic breast cancer at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021. SITC 2021
is taking place in Washington, US and virtually from 10-14 November.
The final OS data will be presented by Immutep at SITC 2021 as a late breaker poster presentation. Interim
OS data from the trial was presented in a spotlight presentation at the San Antonio Breast Cancer Symposium
in December 2020.
from the criteria section prev posted..
- Phase II study showing anti-tumor activity in a novel context
note the word "novel" loosely meaning new, this satisfys general criteria.....
now to the heading mate......
Immutep to present final AIPAC Overall Survival data at SITC.....
Overall survival is what it's all about, we will find out at SITC....but ask yourself,
why did immutep make application for a late breaking abstract if it wasn't for positive news?
Ann: Immutep to present final AIPAC Overall Survival data at SITC, page-18
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.020(6.67%) |
Mkt cap ! $464.8M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 32.3¢ | 30.0¢ | $1.040M | 3.328M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 42705 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |